FibroGen Inc (FGEN) CEO Sells $1,839,459.96 in Stock
FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 38,636 shares of the business’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $47.61, for a total transaction of $1,839,459.96. Following the transaction, the chief executive officer now directly owns 3,029,887 shares of the company’s stock, valued at approximately $144,252,920.07. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of FibroGen Inc (NASDAQ FGEN) traded up $0.05 on Monday, hitting $46.20. 663,105 shares of the stock were exchanged, compared to its average volume of 565,771. The firm has a market capitalization of $3,800.00, a price-to-earnings ratio of -22.76 and a beta of 1.55. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen Inc has a 1-year low of $21.05 and a 1-year high of $60.15.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of FibroGen by 15.1% during the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after buying an additional 761,421 shares during the last quarter. BlackRock Inc. raised its position in FibroGen by 12.3% in the second quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock worth $161,545,000 after purchasing an additional 546,587 shares in the last quarter. FMR LLC raised its position in FibroGen by 96.9% in the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after purchasing an additional 1,641,423 shares in the last quarter. State Street Corp raised its position in FibroGen by 16.4% in the second quarter. State Street Corp now owns 1,763,387 shares of the biopharmaceutical company’s stock worth $56,962,000 after purchasing an additional 248,922 shares in the last quarter. Finally, Hillhouse Capital Management Ltd. raised its position in FibroGen by 75.0% in the second quarter. Hillhouse Capital Management Ltd. now owns 1,750,000 shares of the biopharmaceutical company’s stock worth $56,525,000 after purchasing an additional 750,000 shares in the last quarter. 57.23% of the stock is owned by institutional investors and hedge funds.
A number of research analysts have recently commented on the stock. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. ValuEngine lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 price objective on shares of FibroGen in a research report on Thursday, September 14th. Mizuho assumed coverage on shares of FibroGen in a research report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price objective for the company. Finally, Jefferies Group reaffirmed a “buy” rating and set a $75.00 price objective on shares of FibroGen in a research report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $65.67.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.